Important Considerations: Individual Needs
Other risk factors that may increase vulnerability include: Long duration of diabetes (typically more than 10 years) Poor glycaemic control prior to starting GLP-1 therapy (HbA1c significantly above target) Rapid reduction in HbA1c (a drop of more than 2 percentage points [22 mmol/mol] within 36 months) Concurrent hypertension , especially if poorly controlled Diabetic kidney disease (nephropathy), which often correlates with retinopathy severity Previous history of retinal treatment (laser photocoagulation or intravitreal injections) People with type 2 diabetes but no retinopathy appear to have minimal risk of retinopathy progression based on current evidence
Safety and efficacy of axon therapy (SEAT study), utilizing magnetic peripheral nerve stimulation (mPNS) for treatment of neuropathic pain
The stress of choosing between medication, groceries, utilities, or rent is a burden no one should have to carry
Peripheral neuropathy may take 36 months to improve, and some patients experience incomplete recovery, particularly if treatment was delayed
It is a cell-permeable, selective NNMT inhibitor that does not require cofactors for activity